Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer’s disease
暂无分享,去创建一个
J. Lehrner | J. Furtner | E. Gelpí | T. Traub-Weidinger | R. Wurm | P. Rommer | G. Regelsberger | E. Stögmann | P. Altmann | Tandis Parvizi | Theresa König | S. Klotz | S. Silvaieh
[1] John K. Yue,et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders , 2022, Nature Reviews Neurology.
[2] W. M. van der Flier,et al. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline , 2022, Neurology.
[3] J. Rowe,et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[4] J. Clarimón,et al. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia , 2021, Translational Neurodegeneration.
[5] K. Blennow,et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum , 2021, JAMA neurology.
[6] K. Blennow,et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study , 2021, The Lancet Neurology.
[7] P. Hartikainen,et al. GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[8] P. Svenningsson,et al. A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.
[9] W. M. van der Flier,et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. , 2021, The Lancet. Healthy longevity.
[10] K. Blennow,et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment , 2020, Alzheimer's Research & Therapy.
[11] H. Zetterberg,et al. Serum neurofilament light chain withstands delayed freezing and repeated thawing , 2020, Scientific Reports.
[12] H. Weiner,et al. Blood neurofilament light: a critical review of its application to neurologic disease , 2020, Annals of clinical and translational neurology.
[13] M. Freedman,et al. Blood Neurofilament Light Chain: The Neurologist’s Troponin? , 2020, Biomedicines.
[14] W. M. van der Flier,et al. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.
[15] K. Blennow,et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2020, Translational Psychiatry.
[16] J. Kramer,et al. Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage. , 2020, Journal of Alzheimer's disease : JAD.
[17] K. Blennow,et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline , 2020, Acta Neuropathologica.
[18] K. Blennow,et al. Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum , 2020, medRxiv.
[19] L. Kappos,et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis , 2020, Neurology.
[20] G. Frisoni,et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] D. Harvey,et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease , 2019, Alzheimer's & Dementia.
[22] M. DeMarco,et al. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis , 2019, Alzheimer's & dementia.
[23] K. Blennow,et al. Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals , 2019, Alzheimer's & dementia.
[24] K. Blennow,et al. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.
[25] K. Blennow,et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.
[26] K. Blennow,et al. NFL is a marker of treatment response in children with SMA treated with nusinersen , 2019, Journal of Neurology.
[27] Nick C Fox,et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.
[28] K. Blennow,et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.
[29] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[30] Yue-Ming Li,et al. The role of astrocytes in amyloid production and Alzheimer's disease , 2017, Open Biology.
[31] P. Ince,et al. Review: Astrocytes in Alzheimer's disease and other age‐associated dementias: a supporting player with a central role , 2017, Neuropathology and applied neurobiology.
[32] Henrik Zetterberg,et al. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.
[33] Henrik Zetterberg,et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.
[34] K. Blennow,et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy , 2016, Annals of clinical and translational neurology.
[35] P. Scheltens,et al. Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic , 2015, Alzheimer's & Dementia.
[36] D. Moser,et al. Visuo-constructional functions in patients with mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease , 2015, neuropsychiatrie.
[37] D. Moser,et al. Awareness of memory deficits in subjective cognitive decline, mild cognitive impairment, Alzheimer's disease and Parkinson's disease , 2014, International Psychogeriatrics.
[38] S. Engelborghs,et al. Biobanking of CSF: international standardization to optimize biomarker development. , 2014, Clinical biochemistry.
[39] J. Middeldorp,et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease , 2014, Neurobiology of Aging.
[40] D. Moser,et al. Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic—comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia Study , 2013, Alzheimer's & Dementia.
[41] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[42] F. Boutros-Toni,et al. Alzheimer CSF biomarkers in routine clinical setting , 2012, Acta neurologica Scandinavica.
[43] W. Wadsak,et al. Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11C]methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB). , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[44] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[45] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[46] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[47] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[48] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[49] A. Verkhratsky,et al. Astrocytes in Alzheimer’s disease , 2010, Neurotherapeutics.
[50] M. Hautzinger,et al. Reliabilität und Validität des revidierten Beck-Depressionsinventars (BDI-II) , 2007, Der Nervenarzt.
[51] K. Blennow,et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.
[52] K. Blennow,et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[53] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[54] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[55] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[56] P. Lewczuk,et al. Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. , 2019, Journal of Alzheimer's disease : JAD.
[57] J. Brioni,et al. and Alzheimer's disease , 2010 .
[58] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.